ARTICLE | Clinical News
IGN523: Phase I started
March 24, 2014 7:00 AM UTC
Igenica began an open-label, U.S. Phase I trial to evaluate IV IGN523 once weekly for 8 weeks in about 50 patients with relapsed or refractory AML. ...
Igenica began an open-label, U.S. Phase I trial to evaluate IV IGN523 once weekly for 8 weeks in about 50 patients with relapsed or refractory AML. ...